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Introduction {#jah31193-sec-0004}
============

The vascular endothelium is a delicate monolayer of cells lining all blood vessels, which plays important structural and functional roles in initiation and development of cardiovascular diseases (CVD). A properly functioning endothelium is key for cardiovascular health, whereas endothelial dysfunction is associated with numerous disease states. Importantly, endothelial dysfunction is not only a marker but also a contributor to atherosclerotic diseases. Specifically, endothelial dysfunction has been reported to be associated with coronary plaque progression, anatomical complexity, and vulnerability.[1](#jah31193-bib-0001){ref-type="ref"} Furthermore, endothelial function has a substantial role in developing thrombotic complications.[1](#jah31193-bib-0001){ref-type="ref"} Thus, a strategy based on endothelial function assessment might provide a more tailored approach to prevent cardiovascular events. A number of methods to assess endothelial function have been investigated. Initially, endothelial function was assessed in coronary arteries using an invasive method during cardiac catheterization. More recently, several noninvasive methods for assessment of endothelial function have been developed. Studies of brachial artery flow‐mediated dilation (FMD) have been reported since 1992,[2](#jah31193-bib-0002){ref-type="ref"} and it is the most widely used method in clinical research. Reactive hyperemia--peripheral arterial tonometry (RH‐PAT) is a newly developed method. In 2002, RH‐PAT was reported to be the test for peripheral vascular endothelial function,[3](#jah31193-bib-0003){ref-type="ref"} and its use has been rapidly increasing. The RH‐PAT technique is less operator dependent and uses a contralateral arm as its internal control to correct for systemic changes during testing. Both methods are based on the same principle of reactive hyperemia phenomenon: that is, increased blood flow following a period of transient arterial occlusion, which serves as an index of endothelium‐dependent vasodilator function. FMD assesses the endothelial response to shear stress in the brachial artery as a result of hyperemia, whereas RH‐PAT measures the actual hyperemia. However, these methods differ in target vasculature: the brachial artery diameter in FMD versus a finger arterial pulse wave in RH‐PAT. The Framingham Heart Study reported no statistically significant relationship between signals obtained with RH‐PAT and FMD, suggesting that these reflect distinct aspects of vascular function.[4](#jah31193-bib-0004){ref-type="ref"} Although both tests have been reported to predict cardiovascular events,[5](#jah31193-bib-0005){ref-type="ref"}, [6](#jah31193-bib-0006){ref-type="ref"}, [7](#jah31193-bib-0007){ref-type="ref"} their relative value for predicting cardiovascular risk has not been directly compared, to date. Previously, 2 meta‐analyses on the prognostic value of FMD have been reported,[5](#jah31193-bib-0005){ref-type="ref"}, [6](#jah31193-bib-0006){ref-type="ref"} and Xu et al[7](#jah31193-bib-0007){ref-type="ref"} reported another meta‐analysis of the prognostic value of both FMD and RH‐PAT. However, only 3 RH‐PAT studies were included in their meta‐analysis, and 2 methods were not directly compared. Since then, several additional prospective studies have been published focusing on the prognostic value of these tests.

Therefore, in this systematic review with meta‐analysis, we aimed to update the evidence of FMD and RH‐PAT as predictors of cardiovascular events, and compare the prognostic magnitude on cardiovascular risk between these 2 methods.

Methods {#jah31193-sec-0005}
=======

This systematic review and meta‐analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement, and in accordance with the Meta‐analysis Of Observational Studies in Epidemiology (MOOSE) guidelines.

Data Sources and Search Strategies {#jah31193-sec-0006}
----------------------------------

A comprehensive search of several databases from each database\'s earliest inception to September 24, 2014 was conducted and updated on December 4. The databases included Ovid Medline In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, and Ovid Cochrane Database of Systematic Reviews. The strategy to search potentially relevant prospective observational studies investigating FMD or Reactive hyperemia index (RHI) as assessed by RH‐PAT and cardiovascular event risk was designed and conducted by an experienced librarian with input from the study\'s principal investigator. Controlled vocabulary supplemented with keywords was used to search for studies of endothelial function tests for cardiovascular events. The actual strategy is available in Data S1. We also manually searched PubMed, Ovid Medline, and references in pertinent articles that were identified during the screening.

Study Selection {#jah31193-sec-0007}
---------------

Two investigators (Y.M. and T.G.K.) independently reviewed all records identified by these search methods. The selection was performed in 2 steps; the first step was abstract review and the second step was full text review. Studies with discrepant decisions in screening of the abstract proceeded to full text review, and discrepancies in full text review were resolved through consensus. Studies were eligible for inclusion in this systematic review if they met the following criteria: (1) study provided original data, (2) prospective observational study with follow‐up time ≥6 months, (3) study reported risk estimates of endothelial function as assessed by brachial FMD or RH‐PAT for cardiovascular events or mortality, (4) study of human adults, and (5) study published in English.

Data Extraction {#jah31193-sec-0008}
---------------

Data from included studies were extracted independently by 2 investigators (Y.M. and T.G.K.) using predetermined forms. Discrepancies found in the verification process were resolved by discussion with a third investigator (A.L.). The following data were extracted (where available): first author, year of publication, years of enrollment of the cohort, sex composition, average age, sample size, duration of follow‐up, characteristics of the population, method of endothelial function assessment, outcome characteristics (number of cardiovascular events and type of events \[eg, cardiovascular death, myocardial infarction, and stroke\]), unadjusted and adjusted hazard ratios (HRs) for continuous value of FMD or logarithmic value of RHI (Ln_RHI), and variables adjusted for. We adopted Ln_RHI rather than RHI because of its skewed distribution. When data were missing or results for continuous value of FMD or Ln_RHI were not reported, the original authors were contacted in an attempt to obtain these data. One study reported risk estimates for RHI.[8](#jah31193-bib-0008){ref-type="ref"} We contacted and asked the authors to transform RHI results to logarithmic value and obtained results with Ln_RHI. The studies were classified according to CVD or non‐CVD population. CVD population included patients with coronary artery disease, chest pain, heart failure, stroke, and peripheral arterial disease. Non‐CVD subjects included those without established CVD (general population, healthy subjects, elderly, postmenopausal women, and patients with coronary risk factors).

Risk Bias Assessment {#jah31193-sec-0009}
--------------------

We followed the recommendations for bias assessment of nonrandomized studies, as suggested by the Cochrane collaboration,[9](#jah31193-bib-0009){ref-type="ref"} and information on the methodological quality of each included study was recorded and quality assessment was performed using the Newcastle‐Ottawa Scale (NOS)[10](#jah31193-bib-0010){ref-type="ref"} by 2 independent investigators (Y.M. and T.G.K.). Disagreement was resolved by discussion with a third investigator (A.L.). The score assessed major classifications: selection (4 items), comparability (1 item), and outcome (3 items) (Figure [1](#jah31193-fig-0001){ref-type="fig"}). A maximum score of 1 was graded for each item, except that related to comparability, which allowed for 2. Total scores were calculated by adding each score for each item. For quality, total scores ranged from 0 (lowest) to 9 (highest), and studies with ≥7 points were considered as good quality. The presence of CVD was defined as the most important covariate that would define comparability. Studies that controlled for the presence of CVD received 1 score, whereas studies that controlled for another important confounder (age, sex, hypertension, diabetes, or dyslipidemia) received an additional score. Since the risk of patients with established coronary heart disease are at 4‐ to 6‐folds higher than those without CVD,[11](#jah31193-bib-0011){ref-type="ref"} we defined sufficient follow‐up duration separately. Studies of patients without CVD at enrollment with median follow‐up time \>5 years were assigned a score of 1, whereas studies of patients with CVD at enrollment with follow‐up time \>1 year were assigned a score of 1. Studies with a follow‐up rate \>80% were assigned a score of 1.

![Scheme of risk bias assessment.](JAH3-4-e002270-g001){#jah31193-fig-0001}

Statistical Methods {#jah31193-sec-0010}
-------------------

The risk estimates of each study were reported as HR or risk ratio (RR). We considered HRs as estimates of RRs. If, in addition to original HRs, the studies reported separate HRs for sex, population health status (CVD and non‐CVD), or outcome (overall cardiovascular events and hard cardiovascular events, which consist of cardiovascular death, myocardial infarction, and stroke), these separate HRs were also pooled for subsequent subgroup analyses. If the original author only provided results for categorical values of FMD or Ln_RHI, we converted it into 1 continuous RR using Greenland and Longnecker\'s covariance‐corrected generalized least‐square trend estimation method.[12](#jah31193-bib-0012){ref-type="ref"} In this meta‐analysis, RR represents the increase in risk per 1% increase in brachial FMD or per 0.1 increase in Ln_RHI. Standard errors, which were calculated from CIs, were used for weighing the studies. A random‐effects model was used for calculating the pooled overall risk estimate. The heterogeneity among studies was evaluated by the Cochran\'s Q‐statistic and the I^2^‐statistic. Values of 25%, 50%, and 75% value for I^2^‐statistic represented low, moderate, and high heterogeneity, respectively.[13](#jah31193-bib-0013){ref-type="ref"} To assess the robustness of our meta‐analysis, we examined the following study characteristics in subgroup analyses: study population (CVD population versus non‐CVD population, age, and sex), sample size, duration of follow‐up, annual event rate, FMD technique (forearm versus upper arm occlusion), study quality, and study outcome (cardiovascular mortality and hard cardiovascular events). Owing to the limited number of RH‐PAT studies, no subgroup analyses were performed. In order to assess the impact on cardiovascular outcomes between FMD and RH‐PAT, a pooled SD for each of FMD and Ln_RHI in all included studies of CVD population was calculated using following equation, and RRs for the pooled SD increase in FMD and Ln_RHI were compared.$$\text{Pooled}\mspace{6mu}\mspace{6mu}\text{SD} = \sqrt{\left\{ {\sum_{i = 1}^{k}{(n_{i} - 1)}U_{i} + {\sum_{i = 1}^{k}n_{i}{({\overline{X}}_{i} - {\overline{X}}_{t})}^{2}}} \right\} \div {(n_{t} - 1)}}$$κ, number of groups; n~i~, number of patients in each group; n~t~, total number of patients; U~i~, unbiased estimate of population variance; ${\overline{X}}_{i}$, mean value of each group; and ${\overline{X}}_{t}$, pooled mean value.

Finally, publication bias was evaluated by examining the asymmetry of funnel plot. All *P* values are 2 tailed and *P*\<0.05 was considered statistically significant. All analyses were performed using the Review Manager, version 5.3.5 (Cochrane Collaboration, Oxford, UK) and R software, version 3.2.0.

Results {#jah31193-sec-0011}
=======

Study Retrieval {#jah31193-sec-0012}
---------------

The process of study selection is shown in Figure [2](#jah31193-fig-0002){ref-type="fig"}. According to our systematic search strategy, 2197 titles were identified from electronic databases, and 3 studies were retrieved via hand searching. After screening the title and abstract, 98 studies were eligible for full text review; of these, 57 were excluded, resulting in 35 FMD studies[14](#jah31193-bib-0014){ref-type="ref"}, [15](#jah31193-bib-0015){ref-type="ref"}, [16](#jah31193-bib-0016){ref-type="ref"}, [17](#jah31193-bib-0017){ref-type="ref"}, [18](#jah31193-bib-0018){ref-type="ref"}, [19](#jah31193-bib-0019){ref-type="ref"}, [20](#jah31193-bib-0020){ref-type="ref"}, [21](#jah31193-bib-0021){ref-type="ref"}, [22](#jah31193-bib-0022){ref-type="ref"}, [23](#jah31193-bib-0023){ref-type="ref"}, [24](#jah31193-bib-0024){ref-type="ref"}, [25](#jah31193-bib-0025){ref-type="ref"}, [26](#jah31193-bib-0026){ref-type="ref"}, [27](#jah31193-bib-0027){ref-type="ref"}, [28](#jah31193-bib-0028){ref-type="ref"}, [29](#jah31193-bib-0029){ref-type="ref"}, [30](#jah31193-bib-0030){ref-type="ref"}, [31](#jah31193-bib-0031){ref-type="ref"}, [32](#jah31193-bib-0032){ref-type="ref"}, [33](#jah31193-bib-0033){ref-type="ref"}, [34](#jah31193-bib-0034){ref-type="ref"}, [35](#jah31193-bib-0035){ref-type="ref"}, [36](#jah31193-bib-0036){ref-type="ref"}, [37](#jah31193-bib-0037){ref-type="ref"}, [38](#jah31193-bib-0038){ref-type="ref"}, [39](#jah31193-bib-0039){ref-type="ref"}, [40](#jah31193-bib-0040){ref-type="ref"}, [41](#jah31193-bib-0041){ref-type="ref"}, [42](#jah31193-bib-0042){ref-type="ref"}, [43](#jah31193-bib-0043){ref-type="ref"}, [44](#jah31193-bib-0044){ref-type="ref"}, [45](#jah31193-bib-0045){ref-type="ref"}, [46](#jah31193-bib-0046){ref-type="ref"}, [47](#jah31193-bib-0047){ref-type="ref"}, [48](#jah31193-bib-0048){ref-type="ref"} and 6 RH‐PAT studies[8](#jah31193-bib-0008){ref-type="ref"}, [49](#jah31193-bib-0049){ref-type="ref"}, [50](#jah31193-bib-0050){ref-type="ref"}, [51](#jah31193-bib-0051){ref-type="ref"}, [52](#jah31193-bib-0052){ref-type="ref"}, [53](#jah31193-bib-0053){ref-type="ref"} being eligible for this meta‐analysis. Overall, these studies comprised data from a total of 17 280 participants with FMD, and 1602 with RH‐PAT.

![Flow chart of the study selection procedure. FMD indicates flow‐mediated dilation; RH‐PAT, reactive hyperemia--peripheral arterial tonometry.](JAH3-4-e002270-g002){#jah31193-fig-0002}

Characteristics and Quality Assessment of the Included Studies {#jah31193-sec-0013}
--------------------------------------------------------------

The characteristics of included FMD studies and RH‐PAT studies are shown in Tables [1](#jah31193-tbl-0001){ref-type="table-wrap"} through [3](#jah31193-tbl-0003){ref-type="table-wrap"}, and abstracted in Table [4](#jah31193-tbl-0004){ref-type="table-wrap"}. A total of 16 studies took place in East Asia (China, South Korea, and Japan), 13 studies in Europe (Austria, Denmark, Greece, Italy, Serbia, Spain, and Sweden), and 8 in North America (Canada and United States). Among 35 FMD studies, 13 were derived from a non‐CVD population,[14](#jah31193-bib-0014){ref-type="ref"}, [15](#jah31193-bib-0015){ref-type="ref"}, [16](#jah31193-bib-0016){ref-type="ref"}, [17](#jah31193-bib-0017){ref-type="ref"}, [18](#jah31193-bib-0018){ref-type="ref"}, [19](#jah31193-bib-0019){ref-type="ref"}, [20](#jah31193-bib-0020){ref-type="ref"}, [21](#jah31193-bib-0021){ref-type="ref"}, [22](#jah31193-bib-0022){ref-type="ref"}, [23](#jah31193-bib-0023){ref-type="ref"}, [24](#jah31193-bib-0024){ref-type="ref"}, [25](#jah31193-bib-0025){ref-type="ref"}, [26](#jah31193-bib-0026){ref-type="ref"} and 22 from a CVD population[27](#jah31193-bib-0027){ref-type="ref"}, [28](#jah31193-bib-0028){ref-type="ref"}, [29](#jah31193-bib-0029){ref-type="ref"}, [30](#jah31193-bib-0030){ref-type="ref"}, [31](#jah31193-bib-0031){ref-type="ref"}, [32](#jah31193-bib-0032){ref-type="ref"}, [33](#jah31193-bib-0033){ref-type="ref"}, [34](#jah31193-bib-0034){ref-type="ref"}, [35](#jah31193-bib-0035){ref-type="ref"}, [36](#jah31193-bib-0036){ref-type="ref"}, [37](#jah31193-bib-0037){ref-type="ref"}, [38](#jah31193-bib-0038){ref-type="ref"}, [39](#jah31193-bib-0039){ref-type="ref"}, [40](#jah31193-bib-0040){ref-type="ref"}, [41](#jah31193-bib-0041){ref-type="ref"}, [42](#jah31193-bib-0042){ref-type="ref"}, [43](#jah31193-bib-0043){ref-type="ref"}, [44](#jah31193-bib-0044){ref-type="ref"}, [45](#jah31193-bib-0045){ref-type="ref"}, [46](#jah31193-bib-0046){ref-type="ref"}, [47](#jah31193-bib-0047){ref-type="ref"}, [48](#jah31193-bib-0048){ref-type="ref"} (2 studies[14](#jah31193-bib-0014){ref-type="ref"}, [29](#jah31193-bib-0029){ref-type="ref"} reported results of non‐CVD and CVD samples separately). Contrarily, all RH‐PAT studies derived from a CVD population.[8](#jah31193-bib-0008){ref-type="ref"}, [49](#jah31193-bib-0049){ref-type="ref"}, [50](#jah31193-bib-0050){ref-type="ref"}, [51](#jah31193-bib-0051){ref-type="ref"}, [52](#jah31193-bib-0052){ref-type="ref"}, [53](#jah31193-bib-0053){ref-type="ref"} The years of publication ranged from 2007 to 2014, sample size from 60 to 3025, mean age from 46 to 79, and mean follow‐up duration from 6 to 115 months. FMD studies of CVD subjects had smaller sample sizes, higher male prevalence, shorter follow‐up duration, and higher annual event rate, compared with FMD studies from non‐CVD populations. In comparison with FMD studies, the number of RH‐PAT studies has been increasing recently. Although the overall quality of studies was good, 6 FMD studies[16](#jah31193-bib-0016){ref-type="ref"}, [18](#jah31193-bib-0018){ref-type="ref"}, [23](#jah31193-bib-0023){ref-type="ref"}, [26](#jah31193-bib-0026){ref-type="ref"}, [45](#jah31193-bib-0045){ref-type="ref"}, [47](#jah31193-bib-0047){ref-type="ref"} received a low quality score (≤6). Clinical heterogeneity, in particular differences in end points, had to be taken into consideration.

###### 

Characteristics of FMD Studies of Non‐CVD Subjects

  Study                                                    Description of Study Subjects       Age[a](#jah31193-note-0103){ref-type="fn"}, y   Male   Follow‐up[a](#jah31193-note-0103){ref-type="fn"}   No. Event   No. Population   Annual Event Rate   End Point
  -------------------------------------------------------- ----------------------------------- ----------------------------------------------- ------ -------------------------------------------------- ----------- ---------------- ------------------- --------------------------------------------------------------------------------------------------------------------------------
  Yeboah, 2007[14](#jah31193-bib-0014){ref-type="ref"}     Elderly                             79                                              42%    60 mo                                              674         2791             4.8%                CV death, MI, coronary revascularization, stroke, CHF, PAD
  Muiesan, 2008[15](#jah31193-bib-0015){ref-type="ref"}    Hypertension                        56                                              59%    95 mo                                              32          172              2.4%                Sudden death, MI, UA, angina, coronary revascularization, arrhythmia, stroke, TIA, CHF, PAD
  Rossi, 2008[16](#jah31193-bib-0016){ref-type="ref"}      Postmenopausal women                54                                              0%     45 mo                                              90          2264             1.1%                Cardiac death, MI, coronary revascularization, stroke, TIA
  Suzuki, 2008[17](#jah31193-bib-0017){ref-type="ref"}     General population                  67                                              43%    81 mo                                              84          819              1.5%                Vascular death, MI, stroke
  Morimoto, 2009[18](#jah31193-bib-0018){ref-type="ref"}   CKD with hemodialysis               61                                              56%    43 mo                                              14          199              2.0%                CV death
  Yeboah, 2009[19](#jah31193-bib-0019){ref-type="ref"}     General population                  61                                              49%    60 mo                                              182         3025             1.2%                CV death, resuscitated cardiac arrest, MI, UA, angina, coronary revascularization, stroke
  Akishita, 2010[20](#jah31193-bib-0020){ref-type="ref"}   Men with CV risk factors            48                                              100%   77 mo                                              20          171              1.8%                Cardiac death, CAD, stroke, PAD
  Anderson, 2011[21](#jah31193-bib-0021){ref-type="ref"}   Male firefighter                    49                                              100%   86 mo                                              71          1574             0.6%                CV death, resuscitated cardiac arrest, MI, coronary/carotid/peripheral artery revascularization, vascular disease, stroke, TIA
  Lind, 2011[22](#jah31193-bib-0022){ref-type="ref"}       General population of 70 y of age   70                                              47%    62 mo                                              101         921              2.1%                All‐cause death, MI, stroke
  Yilmaz, 2011[23](#jah31193-bib-0023){ref-type="ref"}     CKD without dialysis                46                                              52%    41 mo                                              89          304              8.6%                CV death, MI, stroke, PAD
  Nagai, 2013[24](#jah31193-bib-0024){ref-type="ref"}      Elderly                             71                                              42%    41 mo                                              42          274              4.5%                MI, UA, angina, stroke, TIA, CHF, renal failure, aortic disease, PAD
  Shechter, 2014[25](#jah31193-bib-0025){ref-type="ref"}   Healthy subjects                    54                                              63%    55 mo                                              48          618              1.7%                All‐cause death, MI, angina, coronary revascularization, stroke, CHF
  Lee, 2014[26](#jah31193-bib-0026){ref-type="ref"}        CKD with peritoneal dialysis        50                                              48%    42 mo                                              25          143              4.9%                Fatal and nonfatal ACS, angina requiring coronary revascularization, stroke, TIA, CHF

ACS indicates acute coronary syndrome; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; FMD, flow‐mediated dilation; MI, myocardial infarction; PAD, peripheral arterial disease; TIA, transient cerebral ischemic attack; UA, unstable angina pectoris.

Either mean or median as reported.

###### 

Characteristics of FMD Studies of CVD Subjects

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                           Description of Study Subjects       Age[a](#jah31193-note-0005){ref-type="fn"}, y   Male   Follow‐up[a](#jah31193-note-0005){ref-type="fn"}   No. Events   No. Population   Annual Event Rate   End Point
  --------------------------------------------------------------- ----------------------------------- ----------------------------------------------- ------ -------------------------------------------------- ------------ ---------------- ------------------- ---------------------------------------------------------------------------
  Neunteufl, 2000[27](#jah31193-bib-0027){ref-type="ref"}         Chest pain                          51                                              52%    60 mo                                              27           73               7.4%                All‐cause death, MI, coronary revascularization

  Brevetti, 2003[28](#jah31193-bib-0028){ref-type="ref"}          PAD                                 64                                              90%    23 mo                                              39           131              15.5%               CV death, MI, UA, coronary revascularization, stroke, TIA, PAD

  Fathi, 2004[29](#jah31193-bib-0029){ref-type="ref"}             CAD\                                58                                              60%    24 mo                                              70           444              7.9%                All‐cause death, MI, UA, coronary revascularization, stroke
                                                                  CKD with dialysis\                                                                                                                                                                              
                                                                  CV risk factors                                                                                                                                                                                 

  Katz, 2005[30](#jah31193-bib-0030){ref-type="ref"}              Chronic HF with NYHA class II‐III   54                                              84%    28 mo                                              17           149              4.9%                All‐cause death, heart transplantation

  Karatzis, 2006[31](#jah31193-bib-0031){ref-type="ref"}          NSTE‐ACS                            63                                              100%   25 mo                                              20           98               9.9%                CV death, ACS, stroke

  Huang, 2007[32](#jah31193-bib-0032){ref-type="ref"}             PAD                                 66                                              74%    10 mo                                              50           267              22.5%               CV death, MI, UA, stroke, CHF

  Hu, 2008[33](#jah31193-bib-0033){ref-type="ref"}                Chest pain                          62                                              58%    16 mo                                              36           279              9.7%                CV death, MI, UA, stroke, CHF

  Takase, 2008[34](#jah31193-bib-0034){ref-type="ref"}            Chest pain                          62                                              77%    50 mo                                              15           103              3.5%                Cardiac death, MI, UA, CHF

  Shechter, 2009[35](#jah31193-bib-0035){ref-type="ref"}          Chronic HF with NYHA class IV       64                                              92%    14 mo                                              30           82               31.4%               All‐cause death, MI, CHF

  Ulriksen, 2009[36](#jah31193-bib-0036){ref-type="ref"}          Chest pain                          54                                              76%    50 mo                                              90           223              9.7%                CV death, MI, UA, coronary revascularization

  Wang, 2009[37](#jah31193-bib-0037){ref-type="ref"}              STEMI                               62                                              66%    12 mo                                              29           101              28.5%               Cardiac death, MI, UA, coronary revascularization, stroke, CHF

  Akamatsu, 2010[38](#jah31193-bib-0038){ref-type="ref"}          PAD,\                               71                                              93%    47 mo                                              18           93               4.9%                CV death, MI, UA, coronary revascularization, stroke, aortic disease, PAD
                                                                  aortic aneurysm                                                                                                                                                                                 

  Santos‐García, 2011[39](#jah31193-bib-0039){ref-type="ref"}     Stroke                              73                                              58%    48 mo                                              32           120              6.7%                CV death, MI, coronary revascularization, stroke, PAD

  Chan, 2012[40](#jah31193-bib-0040){ref-type="ref"}              Stroke                              67                                              69%    30 mo                                              12           127              3.8%                CV death, ACS, coronary revascularization, stroke, CHF, PAD

  Takishima, 2012[41](#jah31193-bib-0041){ref-type="ref"}         Chronic HF                          66                                              68%    33 mo                                              33           245              4.9%                Cardiac death, CHF

  Careri, 2013[42](#jah31193-bib-0042){ref-type="ref"}            NSTE‐ACS                            62                                              73%    32 mo                                              14           60               8.8%                Cardiac death, ACS, angina

  Nakamura, 2013[43](#jah31193-bib-0043){ref-type="ref"}          CAD                                 63                                              71%    52 mo                                              69           547              2.9%                Cardiac death, MI, UA, stroke

  Savic‐Radojevic, 2013[44](#jah31193-bib-0044){ref-type="ref"}   Chronic HF                          59                                              62%    13 mo                                              11           120              8.4%                All‐cause death

  Sedlak, 2013[45](#jah31193-bib-0045){ref-type="ref"}            Women with chest pain               58                                              0%     115 mo                                             83           377              2.3%                All‐cause death, MI, stroke, CHF

  Tarro Genta, 2013[46](#jah31193-bib-0046){ref-type="ref"}       Chronic HF                          65                                              86%    17 mo                                              19           71               18.9%               Cardiac death, heart transplantation, LVAD implantation

  Sawada, 2013[47](#jah31193-bib-0047){ref-type="ref"}            CAD                                 69                                              76%    6 mo                                               25           111              45.0%               All‐cause death, MI, target vessel revascularization

  Hafner, 2014[48](#jah31193-bib-0048){ref-type="ref"}            PAD                                 67                                              67%    50 mo                                              49           184              6.4%                CV death
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACS indicates acute coronary syndrome; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; FMD, flow‐mediated dilation; HF, heart failure; LVAD, left ventricular assist device; MI, myocardial infarction; NSTE‐ACS, non‐ST‐segment elevation acute coronary syndrome; NYHA, New York Heart Association; PAD, peripheral arterial disease; STEMI, ST‐segment elevation myocardial infarction; TIA, transient cerebral ischemic attack; UA, unstable angina pectoris.

Either mean or median as reported.

###### 

Characteristics of RH‐PAT Studies

  Study                                                       Description of Study Subjects   Age[a](#jah31193-note-0007){ref-type="fn"}, y   Male   Follow‐up[a](#jah31193-note-0007){ref-type="fn"}   No. Events   No. Population   Annual Event Rate   End Point
  ----------------------------------------------------------- ------------------------------- ----------------------------------------------- ------ -------------------------------------------------- ------------ ---------------- ------------------- ---------------------------------------------------------------------------------
  Rubinshtein, 2010[49](#jah31193-bib-0049){ref-type="ref"}   Chest pain                      54                                              52%    70 mo                                              86           270              5.5%                CV death, MI, coronary revascularization, hospitalization for any cardiac cause
  Akiyama, 2012[50](#jah31193-bib-0050){ref-type="ref"}       HFPEF                           72                                              50%    20 mo                                              59           321              11.0%               CV death, MI, UA, coronary revascularization, stroke, CHF
  Matsue, 2013[51](#jah31193-bib-0051){ref-type="ref"}        HFPEF                           75                                              44%    10 mo                                              32           159              24.2%               Heart failure--related death, CHF
  Matsuzawa, 2013[52](#jah31193-bib-0052){ref-type="ref"}     Chest pain                      67                                              69%    34 mo                                              105          528              7.0%                CV death, MI, UA, coronary revascularization, stroke, HF, aortic disease, PAD
  Ikonomidis, 2014[8](#jah31193-bib-0008){ref-type="ref"}     CAD                             60                                              86%    34 mo                                              12           111              3.8%                All‐cause death, MI
  Matsue, 2014[53](#jah31193-bib-0053){ref-type="ref"}        CAD                             67                                              74%    31 mo                                              22           213              4.0%                Death due to CAD, MI, angina

CAD indicates coronary artery disease; CHF, congestive heart failure; CV, cardiovascular; HFPEF, heart failure with preserved ejection fraction; MI, myocardial infarction; PAD, peripheral arterial disease; RH‐PAT, reactive hyperemia--peripheral arterial tonometry; UA, unstable angina pectoris.

Either mean or median as reported.

###### 

Summary of Study Characteristics

                                FMD Studies of Non‐CVD Subjects N=13   FMD Studies of CVD Subjects N=22             RH‐PAT Studies N=6
  ----------------------------- -------------------------------------- -------------------------------------------- ---------------------------------------------
  Year of publication                                                                                               
  Median                        2010                                   2010                                         2013[a](#jah31193-note-0009){ref-type="fn"}
  IQR                           2008--2012                             2007--2013                                   2012--2014
  Range                         2007--2014                             2000--2014                                   2010--2014
  Sample size                                                                                                       
  Median                        618                                    124[b](#jah31193-note-0010){ref-type="fn"}   242
  IQR                           186--1919                              97--251                                      147--373
  Range                         143--3025                              60--547                                      111--528
  Mean age, y                                                                                                       
  Median                        56                                     63                                           67
  IQR                           50--69                                 59--66                                       59--73
  Range                         46--79                                 51--73                                       54--75
  Male prevalence, %                                                                                                
  Median                        50                                     72[b](#jah31193-note-0010){ref-type="fn"}    60
  IQR                           42--61                                 61--84                                       48--77
  Range                         0--100                                 0--100                                       44--86
  Mean follow‐up duration, mo                                                                                       
  Median                        60                                     29[b](#jah31193-note-0010){ref-type="fn"}    33
  IQR                           43--79                                 16--50                                       18--43
  Range                         41--95                                 6--115                                       10--70
  Annual event rate, %                                                                                              
  Median                        2.0                                    8.1[b](#jah31193-note-0010){ref-type="fn"}   6.3
  IQR                           1.4--4.7                               4.9--16.4                                    4.0--14.3
  Range                         0.6--8.6                               2.3--45.0                                    3.8--24.2
  Quality score                                                                                                     
  Median                        7                                      8                                            8
  IQR                           6--8                                   7--9                                         7--9
  Range                         4--9                                   5--9                                         7--9
  Low quality score (≤6)                                                                                            
  N (%)                         4 (31)                                 2 (9)                                        0 (0)

CVD indicates cardiovascular disease; FMD, flow‐mediated dilation; IQR, interquartile range; RH‐PAT, reactive hyperemia--peripheral arterial tonometry.

*P*\<0.05 compared with FMD studies of CVD subjects by Wilcoxon test.

*P*\<0.05 compared with FMD studies of non‐CVD subjects by Wilcoxon test.

Pooled Overall Risk Estimate of FMD and RH‐PAT {#jah31193-sec-0014}
----------------------------------------------

Twenty‐six studies[1](#jah31193-note-0002){ref-type="fn"} reported an unadjusted risk estimate of FMD, and 28[2](#jah31193-note-0003){ref-type="fn"} reported an adjusted value, whereas 5 RH‐PAT studies[49](#jah31193-bib-0049){ref-type="ref"}, [50](#jah31193-bib-0050){ref-type="ref"}, [51](#jah31193-bib-0051){ref-type="ref"}, [52](#jah31193-bib-0052){ref-type="ref"}, [53](#jah31193-bib-0053){ref-type="ref"} reported both, and one[8](#jah31193-bib-0008){ref-type="ref"} reported only an adjusted value. Both adjusted and unadjusted pooled RRs were significant for both FMD (per 1% increase: unadjusted RR 0.88, 95% CI 0.86--0.91, adjusted RR 0.88, 95% CI 0.84--0.91, Figures [3](#jah31193-fig-0003){ref-type="fig"} and [4](#jah31193-fig-0004){ref-type="fig"}) and Ln_RHI (per 0.1 increase: unadjusted RR 0.76, 95% CI 0.65--0.88, adjusted RR 0.79, 95% CI 0.71--0.87, Figures [5](#jah31193-fig-0005){ref-type="fig"} and [6](#jah31193-fig-0006){ref-type="fig"}). Except for the adjusted RR estimates for Ln_RHI, significant between‐study heterogeneity was observed.

![Forest plot of unadjusted risk ratio of FMD for cardiovascular events. CV indicates cardiovascular; FMD, flow‐mediated dilation; RR, risk ratio.](JAH3-4-e002270-g003){#jah31193-fig-0003}

![Forest plot of adjusted risk ratio of FMD for cardiovascular events. CV indicates cardiovascular; FMD, flow‐mediated dilation; RR, risk ratio.](JAH3-4-e002270-g004){#jah31193-fig-0004}

![Forest plot of unadjusted risk ratio of Ln_RHI for cardiovascular events. CV indicates cardiovascular; Ln_RHI, logarithmic value of reactive hyperemia index; RR, risk ratio.](JAH3-4-e002270-g005){#jah31193-fig-0005}

![Forest plot of adjusted risk ratio of Ln_RHI for cardiovascular events. CV indicates cardiovascular; Ln_RHI, logarithmic value of reactive hyperemia index; RR, risk ratio.](JAH3-4-e002270-g006){#jah31193-fig-0006}

Subgroup Analysis of FMD Studies {#jah31193-sec-0015}
--------------------------------

Subgroup analyses were performed only in FMD studies, but not in RH‐PAT studies due to the small number of studies (Table [5](#jah31193-tbl-0005){ref-type="table-wrap"}). Sensitivity analyses were restricted to the studies in which an end point included cardiovascular death, and the studies with hard cardiovascular events as end point showed similar results when compared with the full analyses. The prognostic value of FMD was consistently significant in each subgroup. However, there were significant between‐subgroup heterogeneities regarding baseline CVD status, sex, follow‐up duration, annual event rate, sample size, and study quality. In the CVD population, the prognostic value of FMD for cardiovascular events was higher when compared to the non‐CVD population (RR \[95% CI\] 0.84 \[0.79--0.88\] versus 0.92 \[0.89--0.96\], *P*=0.005). Additionally, in studies with male prevalence ≥half (versus \<half), follow‐up duration \<median (versus ≥median), annual event rate ≥median (versus \<median), sample size \<median (versus ≥median), and quality score \<median (versus ≥median), the association between FMD value and cardiovascular outcomes was stronger.

###### 

Subgroup Analysis of FMD Studies

  Subgroup                                      Unadjusted RR   Adjusted RR                                          
  --------------------------------------------- --------------- ------------------- ------- ---- ------------------- ----------
  All studies                                   26              0.88 (0.86, 0.91)           28   0.88 (0.84, 0.91)   
  Non‐CVD subjects                              10              0.89 (0.84, 0.94)   0.86    12   0.92 (0.89, 0.96)   0.005
  CVD subjects                                  18              0.88 (0.85, 0.92)           17   0.84 (0.79, 0.88)   
  End point includes CV death                   20              0.86 (0.83, 0.90)           21   0.87 (0.83, 0.91)   
  End point includes CV death, MI, and stroke   15              0.86 (0.81, 0.90)           16   0.88 (0.84, 0.92)   
  Mean age ≤62 y, median                        13              0.88 (0.83, 0.92)   0.53    15   0.86 (0.82, 0.91)   0.43
  Mean age \>62 y                               13              0.89 (0.86, 0.93)           13   0.89 (0.84, 0.93)   
  Male prevalence ≥half                         19              0.87 (0.83, 0.90)   0.07    22   0.85 (0.81, 0.88)   \<0.0001
  Male prevalence \<half                        8               0.92 (0.88, 0.96)           7    0.95 (0.92, 0.98)   
  Mean follow‐up ≥43 mo, median                 12              0.92 (0.89, 0.95)   0.007   15   0.91 (0.88, 0.95)   0.005
  Mean follow‐up \<43 mo                        14              0.82 (0.76, 0.89)           13   0.82 (0.77, 0.87)   
  Annual event rate ≥6.4 events per y, median   13              0.85 (0.80, 0.90)   0.030   15   0.82 (0.77, 0.88)   0.010
  Annual event rate \<6.4 events per y          13              0.91 (0.88, 0.95)           13   0.91 (0.87, 0.95)   
  Sample size ≥192, median                      15              0.90 (0.86, 0.93)   0.11    13   0.91 (0.87, 0.95)   0.010
  Sample size \<192                             11              0.84 (0.79, 0.90)           15   0.82 (0.77, 0.88)   
  Forearm occlusion                             19              0.87 (0.84, 0.91)   0.45    19   0.88 (0.83, 0.94)   0.77
  Upper arm occlusion                           7               0.90 (0.85, 0.95)           9    0.87 (0.83, 0.91)   
  Lowest tertile of mean FMD value              9               0.87 (0.81, 0.94)   0.17    8    0.90 (0.85, 0.95)   0.21
  Middle tertile of mean FMD value              6               0.93 (0.88, 0.97)           8    0.91 (0.86, 0.96)   
  Highest tertile of mean FMD value             9               0.87 (0.82, 0.92)           9    0.84 (0.78, 0.90)   
  Quality score \<8 (median)                    12              0.86 (0.80, 0.92)   0.30    12   0.81 (0.76, 0.87)   0.01
  Quality score ≥8                              14              0.90 (0.87, 0.92)           16   0.90 (0.87, 0.94)   

CV indicates cardiovascular; CVD, cardiovascular disease; FMD, flow‐mediated dilation; MI, myocardial infarction; RR, risk ratio.

Comparison Between FMD and PAT {#jah31193-sec-0016}
------------------------------

In comparison to FMD studies of non‐CVD subjects, those of CVD subjects had higher male prevalence, smaller sample size, lower event rate, and shorter follow‐up duration (Table [4](#jah31193-tbl-0004){ref-type="table-wrap"}). Furthermore, all RHI studies were derived from CVD subjects and had good quality. Among studies of CVD population, characteristics of studies including male prevalence, sample size, follow‐up duration, and event rate were not significantly different between FMD and RHI. Therefore, in order to compare these 2 methods, we restricted FMD studies to those of CVD population and good quality. Although the risk ratios for 1% increase in distal occlusion FMD and proximal occlusion FMD were not different as shown in Table [5](#jah31193-tbl-0005){ref-type="table-wrap"}, the distribution of mean values between distal and proximal occlusion FMD were different (*P*=0.02), which would affect pooled SD. Thus, we divided studies into 3 groups: proximal occlusion FMD, distal occlusion FMD, and Ln_RHI. Pooled mean±SD of proximal occlusion FMD, distal occlusion FMD, and Ln_RHI, which was calculated from all studies of CVD population, were 6.4±5.2, 4.3±4.6, and 0.56±0.26, respectively. Table [6](#jah31193-tbl-0006){ref-type="table-wrap"} shows the pooled risk estimates for a 1 SD increase in proximal occlusion FMD (unadjusted RR \[95% CI\] 0.60 \[0.44--0.80\], adjusted 0.61 \[0.44--0.85\]), distal occlusion FMD (unadjusted RR \[95% CI\] 0.47 \[0.35--0.63\], adjusted 0.47 \[0.32--0.67\]), and Ln_RHI (unadjusted RR \[95% CI\] 0.48 \[0.33--0.72\], adjusted 0.54 \[0.42--0.71\]). Pooled RRs for these 3 methods were not significantly different.

###### 

Comparison Between Proximal Occlusion FMD, Distal Occlusion FMD, and Ln_RHI

  ---------------------------------------------------------------------------------------
                            Unadjusted          Adjusted                       
  ------------------------- ------------------- ---------- ------------------- ----------
  Proximal occlusion FMD\   0.60 (0.44, 0.80)   0.0005     0.61 (0.44, 0.85)   0.004
  Mean=6.4%, SD=5.2%                                                           

  Distal occlusion FMD\     0.47 (0.35, 0.63)   \<0.0001   0.47 (0.32, 0.67)   \<0.0001
  Mean=4.3%, SD=4.6%                                                           

  Ln_RHI\                   0.48 (0.33, 0.72)   0.0004     0.54 (0.42, 0.71)   \<0.0001
  Mean=0.56, SD=0.26                                                           
  ---------------------------------------------------------------------------------------

FMD indicates flow‐mediated dilation; Ln_RHI, logarithmic value of reactive hyperemia index; RR, risk ratio.

The relation between FMD or Ln_RHI level and cardiovascular event risk is shown in Figure [7](#jah31193-fig-0007){ref-type="fig"}. An ≈1 SD increase in FMD or Ln_RHI was associated with reduced cardiovascular event risk by half, whereas a 1 SD decrease was associated with doubling of risk.

![Relative risk for FMD and Ln_RHI values. (A) Univariate relative risk and (B) Multivariate relative risk. The relative risk for cardiovascular events in each FMD or Ln_RHI value is relative to the expected event rate with the median value of FMD or Ln_RHI. CV indicates cardiovascular; FMD, flow‐mediated dilation; Ln_RHI, logarithmic value of reactive hyperemia index; RR, risk ratio.](JAH3-4-e002270-g007){#jah31193-fig-0007}

Publication Bias {#jah31193-sec-0017}
----------------

Based on a visual inspection of the funnel plots, there may be publication bias among the included studies. The funnel plot showed asymmetrical distribution of FMD studies, indicating that publication bias may exist (Figure [8](#jah31193-fig-0008){ref-type="fig"}A and [8](#jah31193-fig-0008){ref-type="fig"}B). The small number of RH‐PAT studies limits inference from the funnel plots (Figure [9](#jah31193-fig-0009){ref-type="fig"}A and[9](#jah31193-fig-0009){ref-type="fig"}B).

![Funnel plot of flow‐mediated vasodilation (FMD) studies. Funnel plot of univariate (A) and multivariate (B) risk ratio of FMD.](JAH3-4-e002270-g008){#jah31193-fig-0008}

![Funnel plot of RH‐PAT studies. Funnel plot of univariate (A) and multivariate (B) risk ratio of Ln_RHI. Ln_RHI indicates logarithmic value of reactive hyperemia index; RH‐PAT, reactive hyperemia--peripheral arterial tonometry.](JAH3-4-e002270-g009){#jah31193-fig-0009}

Discussion {#jah31193-sec-0018}
==========

In this systematic review and meta‐analysis, we included 35 FMD and 6 RH‐PAT papers reporting the prognostic utility of peripheral endothelial function. We confirmed that peripheral endothelial function as assessed by FMD or RH‐PAT is a significant predictor of future cardiovascular events. According to the subgroup analysis of FMD studies, this prognostic utility was consistent across diverse population subgroups, although between‐study and between‐subgroup heterogeneity were found. The prognostic magnitudes of these 2 methods in CVD population were similar. A 1 SD deterioration in endothelial function could double the risk of cardiovascular events; conversely, a 1 SD improvement could halve it.

Our findings are in line with previous meta‐analyses that reported a significant association between brachial FMD or finger‐tip RH‐PAT and cardiovascular event risk.[5](#jah31193-bib-0005){ref-type="ref"}, [6](#jah31193-bib-0006){ref-type="ref"}, [7](#jah31193-bib-0007){ref-type="ref"} The only meta‐analysis of RH‐PAT studies was reported by Xu et al in 2014,[7](#jah31193-bib-0007){ref-type="ref"} which included 3 studies and 865 patients. Since then, 3 more RH‐PAT studies have been published, and as a result almost twice as many (1602) subjects with RH‐PAT assessment were included in our meta‐analysis. Recent studies showed that the results of RH‐PAT are better evaluated as a logarithmic value rather than RHI itself due to its abnormal distribution. Thus, while the meta‐analysis by Xu et al was done for 1 increase in RHI (pooled unadjusted RR 0.82 \[0.76--0.89\], and pooled adjusted RR 0.85 \[0.78--0.93\]), the present study reported for 0.1 increase in Ln_RHI (pooled unadjusted RR 0.76 \[0.65--0.88\], and pooled adjusted RR 0.79 \[0.71--0.87\]). In our study, the pooled SD was calculated for Ln_RHI as well.

In clinical research, brachial FMD has been a widely used noninvasive method that used reactive hyperemia after artery occlusion as a trigger for endothelium‐dependent vasodilation. The RH‐PAT technique is semi‐automatic and much simpler than FMD, and can potentially provide better interobserver reproducibility. Test--retest reliability of RH‐PAT has been reported to be very good.[54](#jah31193-bib-0054){ref-type="ref"} Brachial arterial diameter before and after reactive hyperemia‐induced vasodilation is measured by ultrasound in FMD, whereas a finger pulse amplitude is recorded by a hard‐shell‐covered tonometry cuff in RH‐PAT. Therefore, FMD is a measure of vasodilation in a conduit artery, whereas RH‐PAT samples smaller resistance arteries. Although nitric oxide bioavailability plays a substantial role in the both methodologies,[55](#jah31193-bib-0055){ref-type="ref"}, [56](#jah31193-bib-0056){ref-type="ref"} other substances, such as prostaglandin, adenosine, and hydrogen peroxide, can also influence vasodilation in response to shear stress and ischemia in different manners.[57](#jah31193-bib-0057){ref-type="ref"} Vasodilatory responses result from a complex interaction between a variety of these vasoactive substances and vascular smooth muscle, and can differ between conduit arteries and microvessels. Endothelium‐derived nitric oxide might have a more important role in FMD technique than in RH‐PAT. Although it has been reported that RH‐PAT mainly reflects endothelium‐derived nitric oxide,[55](#jah31193-bib-0055){ref-type="ref"} further studies are needed to elucidate the detailed mechanism of RH‐PAT signals. In a study of the Framingham Heart Study cohort, FMD (n=7031) and RH‐PAT (n=4352) were measured. Abnormal FMD was related to advancing age, hypertension, and obesity, whereas abnormal RH‐PAT was associated with obesity, increasing total/high‐density lipoprotein cholesterol ratio, diabetes, and smoking. Lower systolic blood pressure was also associated with abnormal RH‐PAT. Interestingly, after adjustment for risk factors and underlying CVD, RH‐PAT was not significantly associated with FMD. Thus, brachial FMD and digital RH‐PAT had differing relations with cardiovascular risk factors and provide distinct information regarding vascular function in conduit versus smaller digital vessels. Nevertheless, our results demonstrated that both methods provide significant predictive value for cardiovascular events and that their prognostic magnitudes in CVD population are similar. Future studies are needed to explore whether the prognostic values of these 2 for cardiovascular events are synergistic or independent of each other.

Results of brachial FMD vary across institutions, and thus, it is difficult to compare between institutions.[58](#jah31193-bib-0058){ref-type="ref"} In this meta‐analysis, mean values of proximal and distal FMD varied from 2.1% to 6.5% (median 3.7, interquartile range 2.5--5.4) and 4.7% to 9.1% (median 5.8, interquartile range 4.8--8.7) even when limited to CVD population, while mean values of Ln_RHI ranged from 0.28 to 0.59 (median 0.54, interquartile range 0.45--0.57) (excluding the 0.28 value results in a range of 0.50--0.59). It might be partly explained by operator dependency, technical factors, and methodological varieties of FMD measurement; therefore it is challenging to conduct a review of brachial artery FMD. On the other hand, the RH‐PAT technique is less operator dependent and well standardized. We showed that cardiovascular risk change associated with a 1 SD change in test value is comparable between FMD and Ln_RHI. Specifically, a 1 SD decrease in distal occlusion FMD from the mean value corresponds to decrease from 4.3% to −0.3%, and in Ln_RHI (RHI) from 0.56 (1.76) to 0.31 (1.36). The brachial artery must not respond or constrict in order to achieve a 1 SD change.

In current clinical practice, CVD risk is estimated based on identifying and quantifying the established risk factors, while there is a notable interindividual heterogeneity in response to risk factors and therapies.[1](#jah31193-bib-0001){ref-type="ref"} Furthermore, nontraditional and unknown risk factors may also have a substantial role in atherosclerosis. By measuring endothelial function, we can directly assess the functional significance of atherogenesis. Thus, noninvasive peripheral endothelial function tests seem to be feasible and effective in cardiovascular risk stratification. However, further evidence is needed, especially on RH‐PAT.

Limitations {#jah31193-sec-0019}
-----------

The limitations of this study must be considered. First, study subjects, sample size, follow‐up duration, end points, and included covariates in multivariable analyses differed among studies. We did not have access to individual subject data to enable consistent adjustments for confounding factors. Second, only papers published in the English language were included. Third, publication bias was suspected from the funnel plots implying probable overestimation of the observed association with important practical implications for the use of endothelial function assessments. Fourth, the number of RH‐PAT studies is small and no studies on non‐CVD subjects with RH‐PAT measures were included.

Conclusions {#jah31193-sec-0020}
===========

The current systematic review and meta‐analysis found that both brachial FMD and digital RH‐PAT have significant predictive value for future cardiovascular events after adjustment for other risk factors. The prognostic magnitudes of these 2 methods in CVD population were similar, and a 1 SD increase or decrease was associated with 50% lower risk or doubled risk of cardiovascular events. Future studies should explore whether the prognostic values of these 2 are independent of each other and whether endothelial function‐guided therapies provide benefits in improving cardiovascular outcomes.
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